A real-world study of the efficacy and safety of furmonertinib for patients with non-small cell lung cancer with EGFR exon 20 insertion mutations
Author:
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Oncology,General Medicine
Link
https://link.springer.com/content/pdf/10.1007/s00432-023-04726-x.pdf
Reference42 articles.
1. Arcila ME, Nafa K, Chaft JE et al (2013) EGFR exon 20 insertion mutations in lung adenocarcinomas: prevalence, molecular heterogeneity, and clinicopathologic characteristics. Mol Cancer Ther 12(2):220–229. https://doi.org/10.1158/1535-7163.Mct-12-0620
2. Choudhury NJ, Schoenfeld AJ, Flynn J et al (2021) response to standard therapies and comprehensive genomic analysis for patients with lung adenocarcinoma with EGFR exon 20 insertions. Clin Cancer Res 27(10):2920–2927. https://doi.org/10.1158/1078-0432.CCR-20-4650
3. Elamin YY, Robichaux JP, Carter BW et al (2022) Poziotinib for EGFR exon 20-mutant NSCLC: clinical efficacy, resistance mechanisms, and impact of insertion location on drug sensitivity. Cancer Cell 40(7):754-767.e756. https://doi.org/10.1016/j.ccell.2022.06.006
4. Fang W, Huang Y, Hong S et al (2019) EGFR exon 20 insertion mutations and response to osimertinib in non-small-cell lung cancer. BMC Cancer 19(1):595. https://doi.org/10.1186/s12885-019-5820-0
5. Han B, Zhou C, Wu L et al (2021) 1210P preclinical and preliminary clinical investigations of furmonertinib in NSCLC with EGFR exon 20 insertions (20ins). Ann Oncol 32:S964
Cited by 3 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. The state of the art of EGFR exon 20 insertions in non-small cell lung cancer: Diagnosis and future perspectives;Cancer Treatment Reviews;2024-03
2. Sunvozertinib: the next candidate of TKI for NSCLC;The Lancet Respiratory Medicine;2023-12
3. Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of YK-029A in Treatment-Naive Patients With Advanced NSCLC Harboring EGFR Exon 20 Insertion Mutations: A Phase 1 Trial;Journal of Thoracic Oncology;2023-09
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3